Tilray To Report Earnings Today: Will It Top Or Flop?
Zacks Investment Research | Aug 12, 2019 09:53PM ET
Tilray, Inc. (NASDAQ:TLRY) , which engages in the research, cultivation, processing, and distribution of medical cannabis, is set to report earnings on Aug 13, after market close. Global marijuana legalization to the rapidly increasing use of CBD as a wellness product should help Tilray witness revenue growth.
In fact, Tilray recently announced the receipt of approval to import cannabis into the United States to conduct two clinical trials related to CBD (cannabidiol). The company had completed a long term, revenue-sharing agreement with Authentic Brands Group to leverage the respective brand portfolios, and develop, market and distribute consumer cannabis products worldwide. The partnership will initially focus on CBD products in the United States and then around the globe.
And these are great news for Tilray as CBD is a sensation right now. We all know that hemp got legalized in the 2018 Farm Bill, following which a slew of hemp-based commodities were sold online and in mom-and-pop stores. However, CBD was placed under the review of the FDA, which recently said that there may be real risks associated with it.
But the regulatory authority acknowledged that there is immense public interest in CBD as a wellness aid. Lest we forget, CBD is widely used in treating pain, inflammation and epilepsy.
Talking about strong demand for CBD, analysts estimated that nearly 65 million Americans have tried CBD and 63% found it effective. What’s more, CBD is a growing industry. Market research firm Brightfield projected that CBD sales in the United States alone will jump 55% to $648 million by the end of this year. In fact, they expect the U.S. hemp CBD market to reach a worth of $22 billion by 2022.
And if we consider a more conservative estimate, the numbers are still encouraging. For instance, investment firm Piper Jaffray forecasted annual U.S. hemp CBD sales of around $15 billion by 2023. Needless to say, companies such as GW Pharmaceuticals plc (NASDAQ:GWPH) , Canopy Growth (NYSE:CGC) and Aurora Cannabis (TSX:ACB) have benefitted immeasurably from venturing into CBD.
Nonetheless, the Zacks Consensus Estimate calls for second-quarter sales growth of more than $40 million for Tilray from the year-ago $9.7 million.
Improved revenue results will surely lead to an uptick in the share price. The Zacks Rank #2 (Buy) company’s expected earnings growth for the current year is pegged at 61.4%, way higher than the Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.